Viewpoint: Spinal muscular atrophy treatment Zolgensma a gene therapy trailblazer, despite controversy

nn kda worlds most expensive drug x
Image: NBC

In August, the US Food and Drug Administration (FDA) gave drug manufacturer AveXis, Inc, a subsidiary of Novartis AG, a major slap on the wrist for violations related to the approval of Zolgensma, a new treatment for spinal muscular atrophy (SMA). The agency said the company had failed to promptly report to the proper regulatory authorities issues of data manipulation in some product testing. Ominous newspaper headlines followed.

It didn’t help that the drug is extremely expensive—a record-setting $2.1 million for a single dose.

But some of the regulatory concerns, at least, seem to be overblown. According to the FDA’s inspection report, the initial data discrepancies were limited to a handful of mouse experiments, and importantly, the human clinical results look sound.

Related article:  Gene therapy pioneer James Wilson makes a comeback after disastrous start

In the eyes of the public and politicians, the reputation of Zolgensma—the first gene replacement therapy to hit the market for a neurological disease—may be tarnished, at least in the near term. But the flurry of media coverage may also have obscured what the drug development community believes to be the more enduring story of Zolgensma: its impact not only on patients but on the entire field of gene therapy.

Read full, original post: News Feature: Gene therapy successes point to better therapies

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
ft covidresponseus feature

Video: Viewpoint: The US wrote the global playbook on the coronavirus and then ignored it

A year ago, the United States was regarded as the country best prepared for a pandemic. Our government had spent ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
globalmethanebudget globalcarbonproject cropped x

Infographic: Cows cause climate change? Agriculture scientist says ‘belching bovines’ get too much blame

A recent interview by Caroline Stocks, a UK journalist who writes about food, agriculture and the environment, of air quality ...
organic hillside sweet corn x

Organic v conventional using GMOs: Which is the more sustainable farming?

Many consumers spend more for organic food to avoid genetically modified products in part because they believe that “industrial agriculture” ...
benjamin franklin x

Are most GMO safety studies funded by industry?

The assertion that biotech companies do the research and the government just signs off on it is false ...
gmo corn field x

Do GMO Bt (insect-resistant) crops pose a threat to human health or the environment?

Bt is a bacterium found organically in the soil. It is extremely effective in repelling or killing target insects but ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies for tighter GMO legislation and famously puts out annual "dirty dozen" list of fruits and ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be the prime mover behind the ongoing campaign against agricultural biotechnology at Consumer Reports. He is an ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend